Loading…
Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Expressing the sense of the Congress with respect to the awareness, prevention, early detection, and effective treatment of viral hepatitis, and for other purposes.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.Con.Res.130, Expressing the sense of the Congress with respect to the awareness, prevention, early detection, and effective treatment of viral hepatitis, and for other purposes. Lobbied for awareness of Hepatitis B. H.R.2090, Food and Drug Administration Improvement Act of 2005. Lobbied to prevent provisions adverse to prescription drug approval process. H.R.5647, Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2007, Lobbied for increased funding for AIDS Drug Assistance Program. H.R.328, Pharmaceutical Market Access Act of 2005, Lobbied to ensure safety of prescription drugs. H.R.700, Pharmaceutical Market Access Act of 2005, Lobbied to ensure safety of prescription drugs. H.R.870,Federal Food, Drug and Cosmetic Act , Lobbied to ensure the safety of prescription drugs. H.R.898, Stroke Treatment and Ongoing Prevention Act, Lobbied for passage of the bill. H.R. 4550, The National Hepatitis B Awareness Act, Lobbied to raise awareness about Hepatitis B and for passage of the bill. H.R. 3559, Medicare DME Access Act, Lobbied to remove certain DME services from competitive bidding, implement quality standards, and passage of the bill. S.1064, Stroke Treatment and Ongoing Prevention Act, Lobbied for passage of the bill. S.3558, The National Hepatitis B Awareness Act of 2006, lobbied to raise awareness about Hepatitis B and for passage of the bill. S.3582, to prohibit bran name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, Lobbied to ensure the orderly transition of drugs from "innovation" to "generic" status. WIC (no bill), Lobbied for improved nutrition and funding sources for the Supplemental Feeding Program for Women, Infants, and Children.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2006 · mid_year · MM
H.R.2090, Food and Drug Administration Improvement Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. H.R.753, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs. H.R.870, Pharmaceutical Research and Manufacturers Accountability Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.16, Affordable Health Care Act, Lobbied to prevent provisions adverse to prescription drug approval process. S.930, Food and Drug Administration Safety Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.184, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs. S.470, FACT Act, Fair Access to Clinical Trials Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.3650, The Helping to Fill the Medicare Rx Gap Act, lobbied for final passage of the bill.
Source: Senate LDA
Establishing the congressional budget for the United States Government for fiscal year 2007 and setting forth appropriate budgetary levels for fiscal years 2008 through 2011.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.563, Prescription Drug Affordability Act of 2005, Lobbied to prevent passage of the bill. Lobbied to remove federally imposed cap on Puerto Rico for Medicaid funding. H.R.4939, Emergency Supplemental Appropriations Act of Defense, the Global War on Terror, and Hurricane Recovery, 2006, Lobbied to preserve the market based Medicare Part D Rx drug benefit.H.Con.Res.373, Establishing the congressional budget for the United States Government for fiscal year 2007, Lobbied to preserve the Medicare Part D drug benefit. H.R.376, Medicare's Equitable Drugs for Seniors Act of 2005, Lobbied against signing a discharge petition to bring this bill to a floor vote.
Establishing the congressional budget for the United States Government for fiscal year 2007 and setting forth appropriate budgetary levels for fiscal years 2008 through 2011.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.5647, Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act 2006. Lobbied for increased funding for Ryan White program. H.R.5122, National Defense Authorization Act for FY2007, Lobbied to ensure safety and access to prescription drugs. H.Con.Res.376, Establishing the congressional budget for the United States Government for fiscal year 2006, revising appropriate budgetary levels for fiscal year 2005, and setting forth appropriate budgetary levels for fiscal year 2008 through 2011. Lobbied against an amendment to remove language from the MMA prohibiting HHS from interfacing in negotiations for the drug benefit. H.R.5384, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2007. Lobbied to ensure safety of prescription drugs.
Stroke Treatment and Ongoing Prevention Act of 2005
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.Con.Res.130, Expressing the sense of the Congress with respect to the awareness, prevention, early detection, and effective treatment of viral hepatitis, and for other purposes. Lobbied for awareness of Hepatitis B. H.R.2090, Food and Drug Administration Improvement Act of 2005. Lobbied to prevent provisions adverse to prescription drug approval process. H.R.5647, Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2007, Lobbied for increased funding for AIDS Drug Assistance Program. H.R.328, Pharmaceutical Market Access Act of 2005, Lobbied to ensure safety of prescription drugs. H.R.700, Pharmaceutical Market Access Act of 2005, Lobbied to ensure safety of prescription drugs. H.R.870,Federal Food, Drug and Cosmetic Act , Lobbied to ensure the safety of prescription drugs. H.R.898, Stroke Treatment and Ongoing Prevention Act, Lobbied for passage of the bill. H.R. 4550, The National Hepatitis B Awareness Act, Lobbied to raise awareness about Hepatitis B and for passage of the bill. H.R. 3559, Medicare DME Access Act, Lobbied to remove certain DME services from competitive bidding, implement quality standards, and passage of the bill. S.1064, Stroke Treatment and Ongoing Prevention Act, Lobbied for passage of the bill. S.3558, The National Hepatitis B Awareness Act of 2006, lobbied to raise awareness about Hepatitis B and for passage of the bill. S.3582, to prohibit bran name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, Lobbied to ensure the orderly transition of drugs from "innovation" to "generic" status. WIC (no bill), Lobbied for improved nutrition and funding sources for the Supplemental Feeding Program for Women, Infants, and Children.
Dominican Republic-Central America-United States Free Trade Agreement Implementation Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S.1307, Central American Free Trade Agreement, Lobbied for equitable treatment of pharmaceutical products. H.R. 3045, Central American Free Trade Agreement, Lobbied for equitable treatment of pharmaceutical products.
Affordable Health Care Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.2090, Food and Drug Administration Improvement Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. H.R.753, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs. H.R.870, Pharmaceutical Research and Manufacturers Accountability Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.16, Affordable Health Care Act, Lobbied to prevent provisions adverse to prescription drug approval process. S.930, Food and Drug Administration Safety Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.184, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs. S.470, FACT Act, Fair Access to Clinical Trials Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.3650, The Helping to Fill the Medicare Rx Gap Act, lobbied for final passage of the bill.
Pension Security and Transparency Act of 2005
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.4297 Tax Relief Extension Reconciliation Act of 2005, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable deductions. S.1783, R&D Tax Credit, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable tax deductions and to extend the research and development tax credit. H.R.2830R&D Tax Credit, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable tax deductions and to extend the research and development tax credit.
Safe IMPORT Act of 2005
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.2090, Food and Drug Administration Improvement Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. H.R.753, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs. H.R.870, Pharmaceutical Research and Manufacturers Accountability Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.16, Affordable Health Care Act, Lobbied to prevent provisions adverse to prescription drug approval process. S.930, Food and Drug Administration Safety Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.184, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs. S.470, FACT Act, Fair Access to Clinical Trials Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.3650, The Helping to Fill the Medicare Rx Gap Act, lobbied for final passage of the bill.
Lower PRICED Drugs Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.2795, Patent Act of 2005, Lobbied to ensure strong IP protections for prescriptions drugs. H.R.5672, Science, State, Justice, Commerce, and Related Agencies Appropriations Act, 2007, Lobbied to maintain the ability of the U.S. Trade Representative to negotiate intellectual property issues. S.2300, Federal Food, Drug and Cosmetic Act, Lobbied to preserve the exclusivity of innovative prescription drugs.
National Hepatitis B Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.Con.Res.130, Expressing the sense of the Congress with respect to the awareness, prevention, early detection, and effective treatment of viral hepatitis, and for other purposes. Lobbied for awareness of Hepatitis B. H.R.2090, Food and Drug Administration Improvement Act of 2005. Lobbied to prevent provisions adverse to prescription drug approval process. H.R.5647, Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2007, Lobbied for increased funding for AIDS Drug Assistance Program. H.R.328, Pharmaceutical Market Access Act of 2005, Lobbied to ensure safety of prescription drugs. H.R.700, Pharmaceutical Market Access Act of 2005, Lobbied to ensure safety of prescription drugs. H.R.870,Federal Food, Drug and Cosmetic Act , Lobbied to ensure the safety of prescription drugs. H.R.898, Stroke Treatment and Ongoing Prevention Act, Lobbied for passage of the bill. H.R. 4550, The National Hepatitis B Awareness Act, Lobbied to raise awareness about Hepatitis B and for passage of the bill. H.R. 3559, Medicare DME Access Act, Lobbied to remove certain DME services from competitive bidding, implement quality standards, and passage of the bill. S.1064, Stroke Treatment and Ongoing Prevention Act, Lobbied for passage of the bill. S.3558, The National Hepatitis B Awareness Act of 2006, lobbied to raise awareness about Hepatitis B and for passage of the bill. S.3582, to prohibit bran name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, Lobbied to ensure the orderly transition of drugs from "innovation" to "generic" status. WIC (no bill), Lobbied for improved nutrition and funding sources for the Supplemental Feeding Program for Women, Infants, and Children.
Preserve Access to Affordable Generics Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.Con.Res.130, Expressing the sense of the Congress with respect to the awareness, prevention, early detection, and effective treatment of viral hepatitis, and for other purposes. Lobbied for awareness of Hepatitis B. H.R.2090, Food and Drug Administration Improvement Act of 2005. Lobbied to prevent provisions adverse to prescription drug approval process. H.R.5647, Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2007, Lobbied for increased funding for AIDS Drug Assistance Program. H.R.328, Pharmaceutical Market Access Act of 2005, Lobbied to ensure safety of prescription drugs. H.R.700, Pharmaceutical Market Access Act of 2005, Lobbied to ensure safety of prescription drugs. H.R.870,Federal Food, Drug and Cosmetic Act , Lobbied to ensure the safety of prescription drugs. H.R.898, Stroke Treatment and Ongoing Prevention Act, Lobbied for passage of the bill. H.R. 4550, The National Hepatitis B Awareness Act, Lobbied to raise awareness about Hepatitis B and for passage of the bill. H.R. 3559, Medicare DME Access Act, Lobbied to remove certain DME services from competitive bidding, implement quality standards, and passage of the bill. S.1064, Stroke Treatment and Ongoing Prevention Act, Lobbied for passage of the bill. S.3558, The National Hepatitis B Awareness Act of 2006, lobbied to raise awareness about Hepatitis B and for passage of the bill. S.3582, to prohibit bran name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, Lobbied to ensure the orderly transition of drugs from "innovation" to "generic" status. WIC (no bill), Lobbied for improved nutrition and funding sources for the Supplemental Feeding Program for Women, Infants, and Children.
Helping Fill the Medicare Rx Gap Act of 2006
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.2090, Food and Drug Administration Improvement Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. H.R.753, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs. H.R.870, Pharmaceutical Research and Manufacturers Accountability Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.16, Affordable Health Care Act, Lobbied to prevent provisions adverse to prescription drug approval process. S.930, Food and Drug Administration Safety Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.184, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs. S.470, FACT Act, Fair Access to Clinical Trials Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.3650, The Helping to Fill the Medicare Rx Gap Act, lobbied for final passage of the bill.
H.R.2090, Food and Drug Administration Improvement Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. H.R.753, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs. H.R.870, Pharmaceutical Research and Manufacturers Accountability Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.16, Affordable Health Care Act, Lobbied to prevent provisions adverse to prescription drug approval process. S.930, Food and Drug Administration Safety Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.184, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs. S.470, FACT Act, Fair Access to Clinical Trials Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.3650, The Helping to Fill the Medicare Rx Gap Act, lobbied for final passage of the bill.
Food and Drug Administration Safety Act of 2005
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.2090, Food and Drug Administration Improvement Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. H.R.753, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs. H.R.870, Pharmaceutical Research and Manufacturers Accountability Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.16, Affordable Health Care Act, Lobbied to prevent provisions adverse to prescription drug approval process. S.930, Food and Drug Administration Safety Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.184, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs. S.470, FACT Act, Fair Access to Clinical Trials Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.3650, The Helping to Fill the Medicare Rx Gap Act, lobbied for final passage of the bill.
To authorize the duration of the base contract of the Navy-Marine Corps Intranet contract to be more than five years but not more than seven years.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.5647, Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act 2006. Lobbied for increased funding for Ryan White program. H.R.5122, National Defense Authorization Act for FY2007, Lobbied to ensure safety and access to prescription drugs. H.Con.Res.376, Establishing the congressional budget for the United States Government for fiscal year 2006, revising appropriate budgetary levels for fiscal year 2005, and setting forth appropriate budgetary levels for fiscal year 2008 through 2011. Lobbied against an amendment to remove language from the MMA prohibiting HHS from interfacing in negotiations for the drug benefit. H.R.5384, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2007. Lobbied to ensure safety of prescription drugs.
To authorize the duration of the base contract of the Navy-Marine Corps Intranet contract to be more than five years but not more than seven years.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.Con.Res.130, Expressing the sense of the Congress with respect to the awareness, prevention, early detection, and effective treatment of viral hepatitis, and for other purposes. Lobbied for awareness of Hepatitis B. H.R.2090, Food and Drug Administration Improvement Act of 2005. Lobbied to prevent provisions adverse to prescription drug approval process. H.R.5647, Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2007, Lobbied for increased funding for AIDS Drug Assistance Program. H.R.328, Pharmaceutical Market Access Act of 2005, Lobbied to ensure safety of prescription drugs. H.R.700, Pharmaceutical Market Access Act of 2005, Lobbied to ensure safety of prescription drugs. H.R.870,Federal Food, Drug and Cosmetic Act , Lobbied to ensure the safety of prescription drugs. H.R.898, Stroke Treatment and Ongoing Prevention Act, Lobbied for passage of the bill. H.R. 4550, The National Hepatitis B Awareness Act, Lobbied to raise awareness about Hepatitis B and for passage of the bill. H.R. 3559, Medicare DME Access Act, Lobbied to remove certain DME services from competitive bidding, implement quality standards, and passage of the bill. S.1064, Stroke Treatment and Ongoing Prevention Act, Lobbied for passage of the bill. S.3558, The National Hepatitis B Awareness Act of 2006, lobbied to raise awareness about Hepatitis B and for passage of the bill. S.3582, to prohibit bran name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, Lobbied to ensure the orderly transition of drugs from "innovation" to "generic" status. WIC (no bill), Lobbied for improved nutrition and funding sources for the Supplemental Feeding Program for Women, Infants, and Children.
Protecting Priorities and Restoring Budget Disciplines Act of 2002
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.2795, Patent Act of 2005, Lobbied to ensure strong IP protections for prescriptions drugs. H.R.5672, Science, State, Justice, Commerce, and Related Agencies Appropriations Act, 2007, Lobbied to maintain the ability of the U.S. Trade Representative to negotiate intellectual property issues. S.2300, Federal Food, Drug and Cosmetic Act, Lobbied to preserve the exclusivity of innovative prescription drugs.
H.R.563, Prescription Drug Affordability Act of 2005, Lobbied to prevent passage of the bill. Lobbied to remove federally imposed cap on Puerto Rico for Medicaid funding. H.R.4939, Emergency Supplemental Appropriations Act of Defense, the Global War on Terror, and Hurricane Recovery, 2006, Lobbied to preserve the market based Medicare Part D Rx drug benefit.H.Con.Res.373, Establishing the congressional budget for the United States Government for fiscal year 2007, Lobbied to preserve the Medicare Part D drug benefit. H.R.376, Medicare's Equitable Drugs for Seniors Act of 2005, Lobbied against signing a discharge petition to bring this bill to a floor vote.
H.R.5647, Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act 2006. Lobbied for increased funding for Ryan White program. H.R.5122, National Defense Authorization Act for FY2007, Lobbied to ensure safety and access to prescription drugs. H.Con.Res.376, Establishing the congressional budget for the United States Government for fiscal year 2006, revising appropriate budgetary levels for fiscal year 2005, and setting forth appropriate budgetary levels for fiscal year 2008 through 2011. Lobbied against an amendment to remove language from the MMA prohibiting HHS from interfacing in negotiations for the drug benefit. H.R.5384, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2007. Lobbied to ensure safety of prescription drugs.
H.R.4297 Tax Relief Extension Reconciliation Act of 2005, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable deductions. S.1783, R&D Tax Credit, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable tax deductions and to extend the research and development tax credit. H.R.2830R&D Tax Credit, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable tax deductions and to extend the research and development tax credit.
H.R.2795, Patent Act of 2005, Lobbied to ensure strong IP protections for prescriptions drugs. H.R.5672, Science, State, Justice, Commerce, and Related Agencies Appropriations Act, 2007, Lobbied to maintain the ability of the U.S. Trade Representative to negotiate intellectual property issues. S.2300, Federal Food, Drug and Cosmetic Act, Lobbied to preserve the exclusivity of innovative prescription drugs.
S.1307, Central American Free Trade Agreement, Lobbied for equitable treatment of pharmaceutical products. H.R. 3045, Central American Free Trade Agreement, Lobbied for equitable treatment of pharmaceutical products.
H.Con.Res.130, Expressing the sense of the Congress with respect to the awareness, prevention, early detection, and effective treatment of viral hepatitis, and for other purposes. Lobbied for awareness of Hepatitis B. H.R.2090, Food and Drug Administration Improvement Act of 2005. Lobbied to prevent provisions adverse to prescription drug approval process. H.R.5647, Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2007, Lobbied for increased funding for AIDS Drug Assistance Program. H.R.328, Pharmaceutical Market Access Act of 2005, Lobbied to ensure safety of prescription drugs. H.R.700, Pharmaceutical Market Access Act of 2005, Lobbied to ensure safety of prescription drugs. H.R.870,Federal Food, Drug and Cosmetic Act , Lobbied to ensure the safety of prescription drugs. H.R.898, Stroke Treatment and Ongoing Prevention Act, Lobbied for passage of the bill. H.R. 4550, The National Hepatitis B Awareness Act, Lobbied to raise awareness about Hepatitis B and for passage of the bill. H.R. 3559, Medicare DME Access Act, Lobbied to remove certain DME services from competitive bidding, implement quality standards, and passage of the bill. S.1064, Stroke Treatment and Ongoing Prevention Act, Lobbied for passage of the bill. S.3558, The National Hepatitis B Awareness Act of 2006, lobbied to raise awareness about Hepatitis B and for passage of the bill. S.3582, to prohibit bran name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, Lobbied to ensure the orderly transition of drugs from "innovation" to "generic" status. WIC (no bill), Lobbied for improved nutrition and funding sources for the Supplemental Feeding Program for Women, Infants, and Children.
Filing targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2004 · mid_year · MM
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2003 · year_end · YY
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2003 · mid_year · MM
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2003 · mid_year · RA
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2002 · year_end · YY
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2002 · mid_year · MM
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS)
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2001 · year_end · YY
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2001 · year_end · YY
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2001 · mid_year · MM
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2000 · year_end · YA
Filing targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2000 · year_end · YY
Filing targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2000 · mid_year · MM
Filing targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
1999 · mid_year · MM
Filing targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)